ScreenerHero

MLTX MoonLake Immunotherapeutics

NAS · US · Healthcare · Biotechnology · moonlaketx.com
10.77USD-1.64%Mkt Cap: 916.60M $P/E: —

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Na…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap916.60M USD
Enterprise Value496.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-227.32M USD
Revenue/Share—
Last Price10.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.29
PEG—
EV/EBITDA-1.87
EV/Revenue—
P/S—
P/B2.14
EPS (TTM)-3.69
EPS (Forward)-3.33
52W Range
5.9508% of range62.75
52W High62.75 USD
52W Low5.950 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-74.66%
ROA-53.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-196.01M USD
CapEx (TTM)35.00K USD
FCF Margin—
FCF Yield-14.39%
Net Debt-435.50M USD
Net Debt/EBITDA1.64
Balance Sheet
Debt/Equity0.25
Current Ratio12.56
Quick Ratio11.97
Book Value/Sh5.12 USD
Cash/Share6.31 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.54 USD
Upside (mean)+165.0%
Target Range6.000 USD – 50.00 USD
6.000+165.0% to mean50.00
# Analysts13
Ownership
Shares Out.85.11M
Float55.47M
Insiders8.18%
Institutions87.79%
Short Interest
Short Ratio7.0d
Short % Float14.49%
Short % Out.10.51%
Shares Short8.95M
Short (prev mo.)6.82M
Technical
SMA 5014.99 (-28.2%)
SMA 20016.75 (-35.7%)
Beta1.08
S&P 52W Chg16.45%
Avg Vol (30d)1.59M
Avg Vol (10d)1.86M
Technical Indicators
RSI (14)25.1
MACD-1.2111
MACD Signal-1.2380
MACD Hist.+0.0269
BB Upper14.30 USD
BB Middle12.27 USD
BB Lower10.23 USD
BB Width33.25%
ATR (14)0.6763 USD
Vol Ratio (20d)0.71x